ROSELAND

Gaxos Health Expands Medical Advisory Board

Retrieved on: 
Thursday, April 25, 2024
Physical medicine and rehabilitation, Johns Hopkins University, Health care, Sport, Abstract, Testosterone, Private practice, MD, Columbia University, PRP, Intelligence, New York (magazine), Prostate cancer, Erectile dysfunction, Cornell University, Drug, Spine, Patient, Bachelor of Arts, Rehabilitation, Public key certificate, Seton Hall University, Medical Center, Hormone replacement therapy, Injury, Partner, Medical device

Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.

Key Points: 
  • Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.
  • “The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • “An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders.”
    Dr. Eric Margolis, M.D.
  • “We welcome Dr. Margolis and Dr. Pavell to the advisory board as their experience and insight will allow us to create a more fine-tuned solution,” Vadim Mats added.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Retrieved on: 
Wednesday, April 3, 2024
Johns Hopkins Hospital, MLSS, Anesthesia, Risk, Trauma, MD, ESI, CPT, ASC, Injection, Safety, Spine, Pain management, Pain, Physician, Epidural steroid injection, Nursing

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Key Points: 
  • ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
  • PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
  • PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
  • Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.

Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023

Retrieved on: 
Monday, April 1, 2024
Growth, MLSS, Webcast, Telephone, Education, Dental Service Organizations, Operating cost, Hospital, United, CPT, Injection, Pain management, STA, Physician

Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.

Key Points: 
  • Arjan Haverhals, CEO and President of Milestone Scientific, stated, “We achieved solid financial results in 2023, with revenue increasing 11.6% and gross profit increasing 39%.
  • For the year ended December 31, 2023, international revenue was approximately $4.1 million, a decrease of $724,000 compared to December 31, 2022.
  • Gross profit for the year ended December 31, 2023, was $6.8 million versus $4.9 million for the year ended December 31, 2022.
  • Operating loss for the year ended December 31, 2023, was $7.1 million versus $8.8 million for the year ended December 31, 2022.

Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call

Retrieved on: 
Thursday, March 28, 2024
Webcast, Telephone, MLSS, Injection

ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments

Key Points: 
  • ROSELAND, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Monday, April 1, 2024, to discuss the company’s financial results for 2023, as well as the company’s corporate progress and other developments
    The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 222156.
  • A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster4.com/Webcast/Page/2306/50281 .
  • An audio replay of the call will be available through April 15, 2024, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 50281.

Gaxos.ai Regains Compliance with Nasdaq Listing Requirements

Retrieved on: 
Tuesday, March 26, 2024
Intelligence

Roseland, NJ, March 26, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.

Key Points: 
  • Roseland, NJ, March 26, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, announced today that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on March 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on the NASDAQ Capital Market.
  • On July 10, 2023, NASDAQ notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market.
  • Since then, NASDAQ has determined that for the Company’s common stock had traded above the $1.00 minimum bid price requirement for 10 consecutive trading days as of March 21, 2024.
  • Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2), and this matter is now closed.

Gaxos.ai Inc. Announces Closing of $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Retrieved on: 
Friday, March 15, 2024
Intelligence, Sale, Regulation D, Security (finance)

The series A warrants and short-term series B warrants have an exercise price of $5.50 per share and are exercisable immediately upon issuance.

Key Points: 
  • The series A warrants and short-term series B warrants have an exercise price of $5.50 per share and are exercisable immediately upon issuance.
  • The series A warrants expire five and one-half years from the date of issuance and short-term series B warrants expire twenty-four months from the date of issuance.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • The gross proceeds from the offering were $3.5 million, prior to deducting placement agent’s fees and other offering expenses payable by Gaxos.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians

Retrieved on: 
Thursday, March 14, 2024
MLSS, Patient, University, Chronic pain, ESI, Neck pain, Injection, Safety, Spine, Pain management, Physician, Epidural steroid injection, Dentistry

ROSELAND, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables to Omaha Pain Physicians , a comprehensive medical pain management center in Omaha, NE.

Key Points: 
  • ROSELAND, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables to Omaha Pain Physicians , a comprehensive medical pain management center in Omaha, NE.
  • Omaha Pain Physicians is focused on treating patients with acute and chronic pain.
  • Dr. Matthew Stottle completed 10 cases using the CompuFlo Epidural system at Omaha Pain Physicians, in which he reported 100% success.
  • The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.

Gaxos.ai Inc. Announces $3.5 Million Private Placement Priced At-The-Market under Nasdaq Rules

Retrieved on: 
Wednesday, March 13, 2024
Intelligence, Sale, Regulation D, Security (finance)

The series A warrants and short-term series B warrants will have an exercise price of $5.50 per share and will be exercisable immediately upon issuance.

Key Points: 
  • The series A warrants and short-term series B warrants will have an exercise price of $5.50 per share and will be exercisable immediately upon issuance.
  • The private placement is expected to close on or about March 15, 2024, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The gross proceeds from the offering are expected to be approximately $3.5 million, prior to deducting placement agent’s fees and other offering expenses payable by Gaxos.

Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App

Retrieved on: 
Wednesday, March 13, 2024
Intelligence, Health

Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, “Ultiself,” in order to facilitate the development of its tech for Gaxos Health.

Key Points: 
  • Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, “Ultiself,” in order to facilitate the development of its tech for Gaxos Health.
  • The integration of Ultiself’s proprietary technology into Gaxos Health’s proposed product offering will enable enhanced customization and user experience aligning with modern-day consumer’s demands for custom and efficient solutions.
  • This move is expected to accelerate Gaxos Health’s development and help solidify its position in the health and wellness industry.
  • Gaxos is committed to leveraging this new technology to provide value to its customers and stakeholders.

Gaxos.ai Inc. Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 8, 2024

Retrieved on: 
Wednesday, March 6, 2024
Eastern Time Zone, CUSIP, Intelligence

Commencing with the opening of trading on The Nasdaq Capital Market on March 8, 2024, the Company’s common stock will trade on a post-split basis under the same trading symbol, “GXAI”.

Key Points: 
  • Commencing with the opening of trading on The Nasdaq Capital Market on March 8, 2024, the Company’s common stock will trade on a post-split basis under the same trading symbol, “GXAI”.
  • As a result of the reverse stock split, the CUSIP number for the Company’s common stock will be 62911P 300.
  • As a result of the reverse stock split, every 12 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share.
  • Immediately after the reverse stock split becomes effective, the Company will have approximately 981,523 shares of common stock issued and outstanding.